Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA probes paclitaxel-eluting stents, balloons

January 18, 2019 By Sarah Faulkner

FDA-logo-newThe FDA wrote a letter to healthcare providers yesterday on the heels of a meta-analysis that suggested an increased mortality rate after two years in people with peripheral artery disease who were treated with paclitaxel-coated and paclitaxel-eluting devices compared to bare devices.

The agency is “evaluating” the new information presented by the study and recommended that healthcare providers continue closely watching patients who have been treated with the drug-eluting devices.

The FDA added that it plans to assess long-term follow-up data from studies that supported the approval of paclitaxel-coated balloons or paclitaxel-eluting stents in the U.S. Specifically, the regulatory group is slated to focus on causes of death within these studies, paclitaxel dose delivered and patient characteristics.

“There are a number of paclitaxel-coated balloons or paclitaxel-eluting stents approved or under study for peripheral vascular use in the U.S.,” the FDA wrote. “Currently, the FDA believes that the benefits continue to outweigh the risks for approved paclitaxel-coated balloons and paclitaxel-eluting stents when used in accordance with their indications for use.”

Following the publication of the meta-analysis, Medtronic (NYSE:MDT) and Boston Scientific (NYSE:BSX) defended the use of their paclitaxel devices in a report from the Star Tribune.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Boston Scientific, Medtronic

IN CASE YOU MISSED IT

  • W.L. Gore officials think they can spur insulin delivery system innovation
  • Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
  • J&J’s Ethicon launches Vistaseal fibrin sealant
  • Senseonics launches Eversense CGM System with non-adjunctive claim
  • ‘Hubble Space Telescope’ for genomics could yield new drugs, materials
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS